Scientists find a new treatment for inflammatory bowel disease

Credit: CC0 Public Domain.

Scientists from Rutgers University found immune cells in the intestine that are needed to prevent inflammatory bowel disease (IBD), colitis, and Crohn’s disease, which affect 3 million people in the United States.

The study, indicating specific T cells, provides a better understanding of the basic mechanisms behind the disease and should lead to more meaningful treatment for patients.

The research is published in Science Immunology and was conducted by Derek Sant’Angelo et al.

Researchers have been studying the immune response to IBD for the past decade.

In this study, they found that people with IBD most likely have fewer of these dedicated T cells, which are essential for protecting against inflammation, in their intestines.

The researchers found that these dedicated T cells, which are part of the immune system and help the body fight disease, specifically help prevent inflammation in the intestine, which is often caused by what people eat.

This discovery has important potential clinical implications for identifying those at risk for developing IBD.

The new discovery could also be used for potential treatment.

Using cellular therapy, the protective T cells could be transferred to people with IBD, increasing their normally low levels.

The team considers this type of cellular therapy a viable option for treatment.

They say that the limited treatment options have plagued people who suffer from IBD.

They are optimistic that this study can give hope to those patients that a better quality of life is on the horizon.

If you care about bowel disease, please read studies about why some people more likely to have bowel diseases, and common food that could increase risk of dangerous bowel diseases.

For more information about health, please see recent studies about a big cause of irritable bowel syndrome, and results showing this food may worsen inflammatory bowel diseases.

Copyright © 2022 Knowridge Science Report. All rights reserved.